BR9905261A - Uma nova associação medicamentosa de liberação programada - Google Patents

Uma nova associação medicamentosa de liberação programada

Info

Publication number
BR9905261A
BR9905261A BR9905261-0A BR9905261A BR9905261A BR 9905261 A BR9905261 A BR 9905261A BR 9905261 A BR9905261 A BR 9905261A BR 9905261 A BR9905261 A BR 9905261A
Authority
BR
Brazil
Prior art keywords
mononitrate
isosorbide
acetylsalicylic acid
relates
multiparticulate
Prior art date
Application number
BR9905261-0A
Other languages
English (en)
Inventor
Alcebiades De Mendonca Athayde
Original Assignee
Libbs Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Libbs Farmaceutica Ltda filed Critical Libbs Farmaceutica Ltda
Priority to BR9905261-0A priority Critical patent/BR9905261A/pt
Priority to ARP000104271A priority patent/AR025318A1/es
Priority to UY26356A priority patent/UY26356A1/es
Priority to JP2000297275A priority patent/JP2001139469A/ja
Priority to AT00121143T priority patent/ATE254466T1/de
Priority to DE60006625T priority patent/DE60006625D1/de
Priority to EP00121143A priority patent/EP1088554B1/en
Publication of BR9905261A publication Critical patent/BR9905261A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<B>"UMA NOVA ASSOCIAçãO MEDICAMENTOSA DE LIBERAçãO PROGRAMADA"<D>. A presente invenção se relaciona com composições farmacêuticas para uso oral e os processos de obtenção das mesmas. Particularmente, composições com aplicação na terapia/profilaxia de doenças cardiovasculares e/ou de seus sinais/sintomas como, por exemplo, angina péctoris, infarto do miocárdio ou outras doenças vasculares cardíacas, cerebrais ou periféricas. Mais especificamente, o invento se relaciona com formulações combinadas de ácido acetilsalicílico um eficaz agente anti-inflamatório, analgésico e antipirético, amplamente utilizado para o tratamento da artrite reumatóide ou osteoartrite - e 5-mononitrato de isossorbida, em que o 5-mononitrato de isossorbida é veiculado em formas multriparticuladas de liberação programada e o ácido acetilsalicílico veiculado em forma multiparticuladas análoga a do 5-mononitrato de isossorbida ou em formulação de liberação normal, isoladamente, na forma de grânulos ou ainda sob a forma de cristais revestidos.
BR9905261-0A 1999-09-30 1999-09-30 Uma nova associação medicamentosa de liberação programada BR9905261A (pt)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR9905261-0A BR9905261A (pt) 1999-09-30 1999-09-30 Uma nova associação medicamentosa de liberação programada
ARP000104271A AR025318A1 (es) 1999-09-30 2000-08-17 Una nueva asociacion medicamentosa de liberacion programada
UY26356A UY26356A1 (es) 1999-09-30 2000-09-26 "una nueva asociacion medicamentosa de liberacion programada"
JP2000297275A JP2001139469A (ja) 1999-09-30 2000-09-28 新しい徐放性薬剤複合体
AT00121143T ATE254466T1 (de) 1999-09-30 2000-09-29 Zusammensetzung mit kontrollierter freigabe enthaltend 5-isosorbidnitrat und acetylsalicylsäure
DE60006625T DE60006625D1 (de) 1999-09-30 2000-09-29 Zusammensetzung mit kontrollierter Freigabe enthaltend 5-Isosorbidnitrat und Acetylsalicylsäure
EP00121143A EP1088554B1 (en) 1999-09-30 2000-09-29 Controlled release drug association containing 5-isosorbide mononitrate and acetylsalicylic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR9905261-0A BR9905261A (pt) 1999-09-30 1999-09-30 Uma nova associação medicamentosa de liberação programada

Publications (1)

Publication Number Publication Date
BR9905261A true BR9905261A (pt) 2001-07-24

Family

ID=4073907

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9905261-0A BR9905261A (pt) 1999-09-30 1999-09-30 Uma nova associação medicamentosa de liberação programada

Country Status (7)

Country Link
EP (1) EP1088554B1 (pt)
JP (1) JP2001139469A (pt)
AR (1) AR025318A1 (pt)
AT (1) ATE254466T1 (pt)
BR (1) BR9905261A (pt)
DE (1) DE60006625D1 (pt)
UY (1) UY26356A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
CN104644589B (zh) * 2015-03-12 2017-11-21 王加峰 一种单硝酸异山梨酯缓释片及其制备工艺
CN105902509B (zh) * 2015-09-28 2018-08-17 天方药业有限公司 一种复方单硝酸异山梨酯缓释片及其制备方法
CN110151732A (zh) * 2019-07-05 2019-08-23 华裕(无锡)制药有限公司 单硝酸异山梨酯缓释胶囊的制备方法
CN114456187A (zh) * 2020-11-09 2022-05-10 鲁南制药集团股份有限公司 单硝酸异山梨酯棒状晶体及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172183T1 (de) * 1992-07-30 1998-10-15 Cal Int Ltd Ester und kombinationen von einem organischen nitrat und einem salicyclat
WO1998005306A1 (en) * 1996-08-02 1998-02-12 Cal International Limited Controlled release tablet formulation of isosorbide-5-mononitrate
GB9713549D0 (en) * 1996-10-18 1997-09-03 Euro Celtique Sa Pharmaceutical combination formulation

Also Published As

Publication number Publication date
ATE254466T1 (de) 2003-12-15
DE60006625D1 (de) 2003-12-24
UY26356A1 (es) 2000-10-31
JP2001139469A (ja) 2001-05-22
EP1088554A1 (en) 2001-04-04
AR025318A1 (es) 2002-11-20
EP1088554B1 (en) 2003-11-19

Similar Documents

Publication Publication Date Title
EP0311677B1 (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
US4829064A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
Altman Pharmacological therapies for osteoarthritis of the hand: a review of the evidence
CA2267049A1 (en) Pharmaceutical compositions
BRPI0113539B8 (pt) processo para a preparação de composições farmacêuticas para uso com formulações de gelatina macia
GT200100211AA (es) Compuestros de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos. (patentefraccionaria no. 1 de la solicitud de patente de invencion no. pi-2001-0211.
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
AR082167A1 (es) Formas de dosificacion gastrorretentivas
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
HUP0203249A2 (hu) Dipiridamol és mopidamol alkalmazása fibrinfüggő mikrokeringési rendellenességek kezelésére és megelőzésére szolgáló gyógyszer készítésére
Drago et al. Pharmacokinetics of transdermal etofenamate and diclofenac in healthy volunteers
BR9905261A (pt) Uma nova associação medicamentosa de liberação programada
JP2008100924A (ja) 総合感冒薬組み合わせ製剤
BR0308305A (pt) Fórmulas dosadas de liberação controlada
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
MX9304503A (es) Compuestos antiinflamatorios.
ALTINTERİM EFFECTS OF WILLOW BARK Salix alba AND ITS SALICYLATES ON BLOOD COAGULANT
Gargya et al. NSAIDS (Non-Steroidal Anti-Inflammatory Drugs)-their effects and side effects in orthodontic therapy-a review
PT719555E (pt) Utilizacao de melatonina para a preparacao de formas farmaceuticas pulsaveis por via oral
UY26176A1 (es) Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas.
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
Tao et al. Amoxapine-induced tardive dyskinesia
Rindone et al. Potentiation of Warfarin Associated with Salsalate Therapy Resulting in Bleeding

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.